Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 16, 2023 07:02 ET
|
Olema Oncology
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23,...
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023 16:03 ET
|
Olema Oncology
Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarterNew clinical data for palazestrant (OP-1250) to be presented in the...